The invention relates to application of bi-methyl piperazinyl pyranone in preparation of fungal infection resisting drugs and particularly discloses a substituted-piperazinyl-containing substituted pyranone compound 3-(2,5-trans-dimethyl-piperazin-1-ylmethyl)-6-(2-bromo-4,5-dimethoxy-phenyl)-2H-
pyran-2-one or pharmaceutically acceptable salts thereof and a preparation method and medicinal application thereof. The in-vitro
fungal growth inhibition activity of the compound is determined through a micro-dosage liquid-based
dilution method; and shown by experimental results, the 80%
growth inhibition concentration of the substituted pyranone compound to
candida albicans is 125 micrograms / milliliter. Shown by pharmacodynamic results, the compound or pharmaceutically acceptable salts thereof can be expected to be applied to drugs for prevention and treatment of diseases caused by fungal infection.